Randall K. Rader - Concepedia

Author

Randall K. Rader

Pfizer (United States)

Also Known As

R K Rader, Randall K. Rader, Randall Rader

Publications

772

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Monsanto (United States)

About

Randall K. Rader is an author at Pfizer (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	474
2	Biochemistry	2	2	90
3	Engineering	1	1	273
4	Social Sciences	1	1	15
5	Biomedical Engineering	1	1	273

Randall K. Rader

Publications

764

Citations

H-Index

Page 1

	Year	Citations
Magnetic resonance contrast enhancement of neovasculature with ?v?3-targeted nanoparticles Stasia A. Anderson, Randall K. Rader, William Westlin, Magnetic Resonance in Medicine NanoparticlesNanomedicineTargeted Contrast AgentAngiogenesisEngineering	2000	273
A small molecule antagonist of the α v β3 integrin suppresses MDA-MB-435 skeletal metastasis John F. Harms, Danny R. Welch, Rajeev S. Samant, Clinical & Experimental Metastasis	2004	111
Experimental ischemia induces a persistent depolarization blocked by decreased calcium and NMDA antagonists Randall K. Rader, Thomas H. Lanthorn Neuroscience Letters Molecular PhysiologySignal TransductionNeurophysiologyMedicinePhysiology	1989	96
Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis Jeffrey D. Peterson, Timothy P. LaBranche, Kristine Vasquez, Arthritis Research & Therapy	2010	67
T cell activation is regulated by voltage-dependent and calcium-activated potassium channels Randall K. Rader, Luisa Kahn, Göran Anderson, The Journal of Immunology	1996	63
cis-2,4-methanoglutamate is a potent and selective N-methyl-D-aspartate receptor agonist Thomas H. Lanthorn, William F. Hood, Gerald B. Watson, European Journal of Pharmacology Molecular PharmacologyBiochemistryFunctional SelectivityMedicineMechanism Of Action	1990	52
Synthesis of pyrazoles and isoxazoles as potent αvβ3 receptor antagonists Thomas D. Penning, Albert Khilevich, Barbara B. Chen, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyBiochemistryMedicinePharmacological AgentPharmacotherapy	2006	38
Novel Tight-Binding Inhibitory Factor-κB Kinase (IKK-2) Inhibitors Demonstrate Target-Specific Anti-Inflammatory Activities in Cellular Assays and following Oral and Local Delivery in an in Vivo Model of Airway Inflammation Cynthia D. Sommers, Janice Thompson, Julia A. Guzova, Journal of Pharmacology and Experimental Therapeutics	2009	33
Novel assay for the influenza virus M2 channel activity Kelleen Giffin, Randall K. Rader, Margaret H. Marino, FEBS Letters	1995	16
Epileptiform activity in vitro can produce long-term synaptic failure and persistent neuronal depolarization Gerald B. Watson, Randall K. Rader, Thomas H. Lanthorn Brain Research Synaptic PlasticityNeurodegenerative DiseasesPersistent Neuronal DepolarizationNeurophysiologyNeurotransmitter	1989	15

Page 1